Proprietary platform for producing and loading exosomes with pharmaceutical cargo targeting spinal cord injuries intranasally

NurExone Biologic focuses on innovative therapies utilizing exosome-based drug delivery systems, particularly through their flagship product, ExoPTEN. Exosomes are nanosized extracellular vesicles that possess a natural ability to target inflamed or damaged tissues, making them an ideal platform for therapeutic applications. By loading these exosomes with small interfering RNA (siRNA) sequences, such as ExoPTEN, the company aims to regenerate and rewire neurons in cases of acute spinal cord injury (SCI). The promising results from laboratory studies indicate that a significant percentage of treated animals regained motor function and bladder control, highlighting the potential of this technology in addressing critical healthcare needs.

The ExoTherapy platform developed by NurExone is designed to produce high-quality exosomes at scale using proprietary bioreactor processes. This platform not only facilitates the loading of known active pharmaceutical ingredients (APIs) onto exosomes but also allows for the repurposing of existing compounds for new therapeutic applications. With the recent FDA Orphan Drug Designation for ExoPTEN, NurExone is positioned to advance its clinical development, with first-in-human trials anticipated in 2025. The company’s commitment to harnessing the regenerative properties of exosomes represents a significant advancement in the field of regenerative medicine and offers a non-invasive approach to treating acute SCI.

Israel

NurExone Biologic is developing a revolutionary biological exosome based technology drug platform to treat damage in the Central Nerve System.
The breakthrough exosome-based technology was proven in preclinical studies to have the potential to treat spinal cord injuries.

NurExone Biologic

Company Details